Arcturus Therapeutics Holdings (ARCT) Earnings Date & Reports

Key Takeaways

• Arcturus Therapeutics (ARCT) is expected to report third-quarter fiscal 2026 results after the market close on Monday, November 9, 2026, covering the quarter ended September 30, 2026.
• Consensus estimates point to a net loss of roughly $0.68 per share on revenue of about $8 million, compared with a loss of $0.49 per share on $17.15 million in revenue in the same period a year earlier.
• Revenue is expected to remain sharply lower year over year following the termination of two collaborations earlier in 2026.
• Investors will be watching closely for pipeline updates, particularly the Phase 3 decision for ARCT-032 in cystic fibrosis and Phase 2 data for ARCT-810 in OTC deficiency.
• The company has a track record of beating consensus loss-per-share estimates, topping expectations in six of its last eight quarters.

Earnings Context and Why It Matters

Arcturus Therapeutics is a late-stage messenger RNA (mRNA) medicines company focused on liver and respiratory rare diseases. Its upcoming report matters less for near-term revenue and more for what it reveals about the clinical pipeline. The company's top line has contracted sharply in 2026 after it ended two agreements — one with Vinbiocare and another with the Israeli Ministry of Health — which removed a major source of collaboration revenue. As a result, investors are treating this quarter primarily as a checkpoint on cash runway, operating expenses, and, most importantly, the timing of key clinical milestones that could reshape the company's value proposition.

Earnings Expectations

For the third quarter of fiscal 2026, Wall Street expects Arcturus to report a loss of approximately $0.68 per share, according to consensus data, with individual estimates ranging from roughly $0.60 to $0.90. Revenue is projected to come in near $8 million. That compares with a loss of $0.49 per share and revenue of $17.15 million in the prior-year quarter, underscoring how much collaboration revenue has declined.

In its most recent report, for the second quarter ended June 30, 2026, the company posted a loss of $0.84 per share on revenue of $2.96 million, beating consensus loss estimates. The first quarter of 2026 similarly delivered a smaller-than-expected loss of $0.95 per share. Because Arcturus is pre-commercial, the key figures investors watch extend beyond the income statement to include research and development (R&D) spending, cash position, and any updates on clinical timelines.

AI Screener

For investors looking to move beyond single-stock analysis, Tickeron's AI Screener offers an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. Explore the AI Screener to refine your own watchlist as earnings season unfolds.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 report is cautiously optimistic. Arcturus shares have experienced notable positive momentum since its August earnings release, reflecting renewed enthusiasm around the pipeline rather than current financials. Still, the stock remains highly sensitive to clinical and regulatory news, which can swing the share price sharply regardless of headline revenue figures.

The main risk factors heading into the report are the continued absence of meaningful revenue, the pace of cash burn, and any delays in clinical readouts. Because the company operates in the high-risk biotechnology space, investors are likely to react more to forward-looking statements from management than to the historical quarter's results.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the Phase 3 decision for ARCT-032, the company's inhaled mRNA therapeutic for cystic fibrosis, which management has signaled could come in the fourth quarter of 2026. This follows a strategic collaboration with Thermo Fisher Scientific announced in July 2026 to advance ARCT-032.

Equally significant is the Phase 2 data readout for ARCT-810, an investigational treatment for ornithine transcarbamylase (OTC) deficiency, a rare genetic liver disorder. That data was expected during the third quarter of 2026, so investors will be listening for confirmation of timing and any preliminary observations.

Beyond clinical milestones, investors should monitor operating expense trends and the company's cash runway. With limited commercial revenue, disciplined spending and sufficient capital are essential to fund late-stage development. Any commentary on financing, partnership opportunities, or manufacturing scale-up will also shape the outlook. As always with clinical-stage biotechs, the key is not a single quarter's numbers, but whether management can execute on its stated timeline for catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations